Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Indian Pharmaceutical Market Outlook Introduction | 10 | 1 |
| Indian Pharmaceutical Market Outlook Overview | 11 | 12 |
| Global Pharmaceutical Industry Landscape | 11 | 1 |
| Macro View of the Indian Pharmaceutical Sector | 12 | 1 |
| Demographic Analysis | 13 | 1 |
| Population Size, Growth, and Structure | 13 | 2 |
| Crude Death Rate | 15 | 1 |
| Infant Mortality Rate | 16 | 1 |
| Life Expectancy at Birth | 17 | 2 |
| Driver and Barriers | 19 | 1 |
| Drivers | 19 | 1 |
| Rising Income Levels and Healthcare Spending | 19 | 1 |
| Expected Increase in the Size of the Healthcare Workforce | 20 | 1 |
| Increase in Reach of Healthcare by National Rural Health Mission | 20 | 1 |
| Increasing Insurance Coverage by Rashtriya Swasthya Bima Yojana and Other Regional Schemes | 20 | 1 |
| Introduction of New Products and Strong Pipeline | 21 | 1 |
| Barriers | 21 | 1 |
| Pricing Policies | 21 | 1 |
| Counterfeiting | 21 | 1 |
| Weak Intellectual Property Rights | 21 | 1 |
| SWOT Analysis of Indian Pharmaceutical Industry | 22 | 1 |
| Indian Pharmaceutical Market Outlook Industry Characteristics | 23 | 14 |
| Healthcare Policy | 23 | 1 |
| National Health Policy 2002 | 23 | 1 |
| National Rural Health Mission | 23 | 1 |
| National Urban Health Mission | 24 | 1 |
| Intellectual Property Rights in India | 25 | 1 |
| Effect of Patent Laws on Pharmaceutical Production in India | 26 | 1 |
| Key Impact of the New Patent Laws on India | 27 | 1 |
| Patent Act 2005 First Step towards Improving IP Protection | 27 | 1 |
| IPR Enforcement Rules 2007 | 27 | 1 |
| Trademarks Bill 2007 | 27 | 1 |
| Drugs and Cosmetics Act (Amendment) 2008 | 27 | 1 |
| Drug Distribution Structure | 28 | 1 |
| National Pharmaceuticals Pricing Policy | 29 | 1 |
| Objectives of the Present Policy | 29 | 1 |
| Key Principles of National Pharmaceuticals Pricing Policy, 2011 | 29 | 1 |
| Principles for Drug Price Control and Determination in National Pharmaceutical Pricing Policy 2011 | 30 | 1 |
| Other Aspects of the Policy | 30 | 1 |
| Impact Analysis of the Policy | 31 | 1 |
| Goods and Services Tax | 31 | 1 |
| An Introduction to Goods and Services Tax | 31 | 1 |
| Dual Goods and Services Tax in India | 31 | 1 |
| Impact on the Pharmaceutical Industry | 32 | 1 |
| Procurement | 32 | 1 |
| Manufacture | 32 | 1 |
| Sales and Distribution | 32 | 1 |
| Pricing | 32 | 1 |
| Research | 32 | 1 |
| Direct Tax Code | 33 | 1 |
| Tax Structure | 33 | 1 |
| Incentives Available to the Pharmaceutical Sector | 33 | 1 |
| Road Ahead | 33 | 1 |
| Healthcare Spending in India | 34 | 1 |
| Insurance and Reimbursement | 35 | 1 |
| Private Health Insurance | 35 | 1 |
| Health Insurance Companies Landscape | 36 | 1 |
| Indian Pharmaceutical Market Outlook Market Analysis | 37 | 9 |
| Market overview | 37 | 1 |
| Contract Research and Manufacturing Services | 37 | 1 |
| Biotech | 38 | 1 |
| Vaccines | 39 | 1 |
| Biosimilars | 39 | 3 |
| Over-the-Counter Drugs | 42 | 1 |
| Prescription Drugs | 42 | 1 |
| Patented Drugs | 42 | 1 |
| Generics | 42 | 1 |
| Herbal Medicines | 43 | 1 |
| Market Segmentation | 44 | 2 |
| Indian Pharmaceutical Market Outlook Market Analysis by Therapeutic Categories | 46 | 17 |
| Market Share of Leading Therapeutic Segment | 46 | 1 |
| Anti-Infectives | 47 | 1 |
| Market Size | 47 | 1 |
| Key Brands and Players | 48 | 1 |
| Recent Developments | 48 | 1 |
| Biological E. Launches Japanese Encephalitis Vaccine Jeev in India September 2012 | 48 | 1 |
| Mylan to Supply Antiretroviral Drugs to National AIDS Control Organization September 2012 | 48 | 1 |
| Venus Remedies Secures First Patent in Canada through Vancoplus September 2012 | 48 | 1 |
| Outlook | 48 | 1 |
| Cardiovascular System | 49 | 1 |
| Market Size | 49 | 1 |
| Recent Developments | 50 | 1 |
| Lupin Receives FDA Approval for Generic Avapro Tablets October 2012 | 50 | 1 |
| AstraZeneca Launches Antiplatelet Drug Brilinta in India October 2012 | 50 | 1 |
| Ranbaxy Misses First-Day Launch of Generic Hypertension Drug Valsartan September 2012 | 50 | 1 |
| Outlook | 50 | 1 |
| Gastrointestinal | 51 | 1 |
| Market Size | 51 | 1 |
| Recent Developments | 52 | 1 |
| Wockhardt Launches Generic Anti-Ulcer Drug LansoPrazole September 2012 | 52 | 1 |
| Synergy Pharma Enters into Agreement with Ironwood Pharma for Plecanatide September 2012 | 52 | 1 |
| Modi-Mundipharma Launches Movicol in India August 2012 | 52 | 1 |
| Outlook | 52 | 1 |
| Diabetes | 53 | 1 |
| Market Size | 53 | 1 |
| Recent Developments | 54 | 1 |
| Diabetology Enters into Licensing Agreement with USV for Capsulin July 2012 | 54 | 1 |
| India and US Sign Agreement to Collaborate on Diabetes Research June 2012 | 54 | 1 |
| Transgene Reports Results from TrabiOral Oral Insulin Studies May 2012 | 54 | 1 |
| Outlook | 54 | 1 |
| Central Nervous System | 55 | 1 |
| Market Size | 55 | 1 |
| Recent Developments | 56 | 1 |
| Pozen Patents Upheld in Treximet Patent Litigation Appeal October 2012 | 56 | 1 |
| BioLineRx to conduct Interim Analysis of Phase II/III CLARITY Clinical Trial of BL-1020 for Treatment of Schizophrenia October 2012 | 56 | 1 |
| Wockhardt Launches Generic Antidepressant Drug Wellbutrin SR September 2012 | 56 | 1 |
| Outlook | 56 | 1 |
| Respiratory | 57 | 1 |
| Market Size | 57 | 1 |
| Recent Developments | 58 | 1 |
| FDA Approves First Generic Versions of Singulair to Treat Asthma and Allergies August 2012 | 58 | 1 |
| Dr. Reddy s Launches Montelukast Sodium Tablets and Montelukast Sodium Chewable Tablets in the US August 2012 | 58 | 1 |
| Sun Pharma Announces FDA Approval of Generic Astelin Nasal Spray May 2012 | 58 | 1 |
| Outlook | 58 | 1 |
| Dermatology | 59 | 1 |
| Market Size | 59 | 1 |
| Recent Developments | 60 | 1 |
| AmDerma Pharma Enters into Licensing Agreement with Oculus Innovative Sciences June 2012 | 60 | 1 |
| Oxygen Biotherapeutics Study Reveals Dermacyte Concentrate's Potential to Relieve Histamine-Induced Pruritus in Healthy Patients May 2012 | 60 | 1 |
| Outlook | 60 | 1 |
| Oncology | 61 | 1 |
| Market Size | 61 | 1 |
| Recent Developments | 62 | 1 |
| Strides Arcolab Receives ANDA Approval for Fludarabine Injection from FDA October 2012 | 62 | 1 |
| Cadila Pharma Files for Cancer Vaccine Patent In India October 2012 | 62 | 1 |
| Piramal Healthcare Receives Approval for Conducting Phase II Clinical Trial of P276 July 2012 | 62 | 1 |
| Outlook | 62 | 1 |
| Indian Pharmaceutical Market Outlook Key Trends | 63 | 11 |
| Rapid Consolidation and Rise of Multinational Corporations in the Indian Pharmaceutical Industry | 63 | 1 |
| M&A Deals | 63 | 2 |
| Licensing Deals | 65 | 1 |
| Partnership Deals | 66 | 1 |
| Patent Litigations Favoring Generics | 67 | 1 |
| Indian Patent Office Revokes Patent for Pfizer s Cancer Drug Sutent (sunitinib) | 67 | 1 |
| Indian Appeals Body Dismisses Bayer s Plea for Stay on Natco's Generic Nexavar (sorafenib) | 67 | 1 |
| Delhi High Court Rules in Favor of Cipla in Roche's Tarceva (erlotinib) Patent Lawsuit | 67 | 1 |
| Indian Supreme Court Asks Novartis to Scale Down Price of Cancer Drug Glivec (imatinib) | 67 | 1 |
| Increasing Importance of Rural Marketing in India | 68 | 1 |
| Case Study - Novartis Arogya Parivar Case Study | 68 | 1 |
| Action Points | 68 | 1 |
| Results | 69 | 1 |
| Product Localization and India-Specific Pricing | 70 | 1 |
| Case Study - GlaxoSmithKline, Localized Business Model | 70 | 1 |
| India-Specific Pricing | 70 | 1 |
| Emphasis on Customized Product Line | 70 | 1 |
| Differential Pricing | 70 | 1 |
| Sales Strategies | 71 | 1 |
| Case Study - Mankind, Sales Excellence | 71 | 1 |
| Patented Products Introduced in Niche Segments | 72 | 1 |
| Case Study - Merck s Successful Strategy for Patented Products | 72 | 1 |
| Introduction | 72 | 1 |
| Better Pharmacological Effect of DPP-4 Inhibitors Helped Rapid Adoption | 72 | 1 |
| Robust Marketing Approach | 72 | 1 |
| Excellent Commercialization Strategy | 72 | 1 |
| Conclusion | 72 | 1 |
| Actions Taken by Indian Government against Counterfeit Drugs | 73 | 1 |
| Indian Pharmaceutical Market Outlook Competitive Landscape | 74 | 11 |
| Key Foreign Companies | 74 | 1 |
| Sanofi | 74 | 1 |
| Company Overview | 74 | 1 |
| Roche | 74 | 1 |
| Business Overview | 74 | 1 |
| AstraZeneca | 75 | 1 |
| Business Overview | 75 | 1 |
| GlaxoSmithKline | 75 | 1 |
| Business Overview | 75 | 1 |
| Abbott Laboratories | 75 | 1 |
| Business Overview | 75 | 1 |
| Key Domestic Companies | 76 | 1 |
| Dr. Reddy s Laboratories | 76 | 1 |
| Business Overview | 76 | 1 |
| Strategy | 77 | 1 |
| Lupin | 78 | 1 |
| Business Overview | 78 | 1 |
| Strategy | 79 | 1 |
| Cipla Limited | 80 | 1 |
| Business Overview | 80 | 1 |
| Strategy | 80 | 1 |
| Ranbaxy Laboratories Limited | 81 | 1 |
| Business Overview | 81 | 1 |
| Strategy | 82 | 1 |
| Biocon | 83 | 1 |
| Business Overview | 83 | 1 |
| Strategy | 84 | 1 |
| Indian Pharmaceutical Market Outlook The Way Forward | 85 | 5 |
| Outlook for the Indian Pharmaceutical Industry | 85 | 1 |
| Risks | 86 | 1 |
| Currency Fluctuation and Financial Problems will make it Difficult to Sustain Growth | 86 | 1 |
| Regulatory Hurdles | 86 | 1 |
| Financial Disparity | 86 | 1 |
| Intellectual Property Concerns | 86 | 1 |
| Unfavorable Patent Law for Bigger Companies | 86 | 1 |
| Recommendations | 87 | 1 |
| Improved Links between Industry and Academia | 87 | 1 |
| Focus on R&D Initiatives and Skilled Manpower | 87 | 1 |
| Support for Clinical Trials Sector | 87 | 1 |
| Quality Drugs to be made Affordable and Accessible | 87 | 1 |
| Opportunities Ahead | 88 | 1 |
| Foreign Direct Investment | 88 | 1 |
| Chronic/Acute | 88 | 1 |
| Strategies for Future Success | 88 | 1 |
| Increasing Importance of Biosimilars | 88 | 1 |
| Rural Markets | 89 | 1 |
| Government s Role | 89 | 1 |
| Indian Pharmaceutical Market Outlook Appendix | 90 | 5 |
| Market Definitions | 90 | 1 |
| Abbreviations | 90 | 2 |
| Bibliography | 92 | 1 |
| Research Methodology | 93 | 2 |
| Coverage | 93 | 1 |
| Secondary Research | 93 | 1 |
| Primary Research | 93 | 1 |
| Expert Panel Validation | 94 | 1 |
| Contact Us | 94 | 1 |
| Disclaimer | 94 | 1 |
